Eli Lilly to Acquire Centessa for $7.8 Billion After UK Court Approval
LLY sits 76% above its 52-week low of $623.78.
Summary
Eli Lilly has received UK court approval to acquire Centessa for approximately $7.8 billion, with the deal expected to close on June 24, 2026. This follows an earlier announcement in April regarding the acquisition of Centessa's OX2R agonist assets for $6.3 billion, indicating an expanded or full company acquisition. This represents a significant strategic investment for Eli Lilly, further strengthening its pipeline and market position. Separately, the company declared a routine Q3 cash dividend of $1.73 per share.
At the time of this announcement, LLY was trading at $1,100.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.